| Purpose：Establish Mycoplasma pneumoniae pneumonia animal model in rats, andresearch the mechanism of Qingzao Jiufei decoction treatment Mycoplasma pneumoniaepneumonia through observing Mycoplasma pneumoniae pneumonia in rat lung tissuepathology, the level of IL-2and TNF-α, provides experimental basis for further clinicalapplication.Material and method：(1) The establishment of Mycoplasma pneumoniae pneumoniain rats model. Totally60rats were randomly divided into model group and control group,with30rats in each, vaccinate0.2ml Mycoplasma pneumoniae bacteria which the concentrationof1×107CCU/mL for model group consecutive3days, while the control group receivedMycoplasma pneumoniae liquid medium0.2ml. In3,5,7,10and14days after inoculationmodeling, two groups of rats were sacrificed, then take left lung pathological examination oflung tissue and pathology score is calculated, take right lung Bronchoalveolar lavage fluid(BALF), the positive rate in BALF MP detection by PCR, and be identified by pathologyscores and PCR model is successful.(2) Research the treatment mechanism of Qingzao Jiufeidecoction for MPP in rats. Totally120rats were randomly divided into normal group, modelgroup, Qingzao Jiufei decoction groups, roxithromycin groups, with30rats in each, usingmethod of (1) to create a model of MPP. From the first day after the start modeling, QingzaoJiufei decoction group rats were given the concentration of50mg/ml Qingzao Jiufeidecoction,and roxithromycin group rats were given the concentration of13mg/mlroxithromycin, while the model group rats, the control group rats given saline, each2.5ml,once a day for10days. In3,5,7,10and14days after inoculation modeling, each group of ratswere sacrificed, then gather the eye take its venous blood in rats, detect the level of IL-2, TNF-αby ELISA; take right lung upper lobe pathological examination of lung tissue and pathologyscore is calculated, take the right lung lower lobe of rats to detect the level of IL-2, TNF-α byimmunohistochemistry. Results：1. The lung tissue pathology score in rats shows that the model group in3days after the startmodeling pathological score gradually increased, reaching a maximum in10days after thestart modeling, in the control group of lung tissue pathology score showed no significantpathological inflammation. PCR results showed that MP-positive rate in Bronchoalveolarlavage fluid in3days after modeling began to rise, in7days to reach100%, in the controlgroup in Bronchoalveolar lavage fluid MP was negative,confirmed that the modeling of MPPsuccess.2. lung pathology scores showed: the pathological score of roxithromycin group, QingzaoJiufei decoction group compared with the model group were started in5and7days aftermodeling decreased,（P＜0.05）; Qingzao Jiufei decoction group compared with theroxithromycin group in3and14days after modeling, pathology score no significantdifference,（P＞0.05）.3. IL-2levels of testing: immunohistochemistry showed that the model group in7days aftermodeling started decreased significantly compared with the normal group,（P＜0.05）;roxithromycin group,Qingzao Jiufei decoction group respectively in7and10days aftermodeling started increased significantly compared with the model group,（P＜0.05）; nosignificant difference between two groups of the number of days,（P＞0.05）. ELASI testshowed that compared with the normal group, model group was significantly lower in3daysafter modeling,（P＜0.05）; roxithromycin group, Qingzao Jiufei decoction group wererespectively in5and7days after modeling started increased significantly compared with themodel group,（P＜0.05）; no significant difference in3and10days after modeling betweenQingzao Jiufei decoction group and roxithromycin group,（P＞0.05）.4. TNF-α levels of testing: immunohistochemistry showed that the model group in7daysafter modeling started increased significantly compared with normal group，（P＜0.05）;roxithromycin group, Qingzao Jiufei decoction grouprespectively in7and10days aftermodeling started decreased significantly compared with the model group,（P＜0.05）; nosignificant difference between two groups of the number of days,（P＞0.05）. ELASI testshowed that compared with the normal group, model group was significantly higher in3days after modeling,（P＜0.05）; roxithromycin group, Qingzao Jiufei decoction group wererespectively in5and7days after modeling started decreased significantly compared with themodel group,（P＜0.05）;no significant difference between Qingzao Jiufei decoction groupand roxithromycin group in3days after modeling,（P＞0.05）.Conclusion：1. Qingzao Jiufei decoction can reduce MPP inflammation of lung tissue in rats, the role ofthe most obvious in the late MP infection.2. Qingzao Jiufei decoction treatment mechanism for MPP may be involved in the regulationof the level of cytokines IL-2, TNF-α that participate in the immune inflammatory response. |
PDF Full Text Request